Ausgabe 3/2018
Inhalt (8 Artikel)
Adjunctive Eslicarbazepine Acetate in Pediatric Patients with Focal Epilepsy: A Systematic Review and Meta-Analysis
Simona Lattanzi, Francesco Brigo, Elisabetta Grillo, Claudia Cagnetti, Alberto Verrotti, Gaetano Zaccara, Mauro Silvestrini
Convergent Mechanisms Underlying Rapid Antidepressant Action
Panos Zanos, Scott M. Thompson, Ronald S. Duman, Carlos A. Zarate Jr., Todd D. Gould
Gadolinium-Based Contrast Agent-Related Toxicities
Luca Pasquini, Antonio Napolitano, Emiliano Visconti, Daniela Longo, Andrea Romano, Paolo Tomà, Maria Camilla Rossi Espagnet
Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
Michael W. Jann, Scott R. Penzak
Newer Antiepileptic Drugs for Status Epilepticus in Adults: What’s the Evidence?
Isabelle Beuchat, Jan Novy, Andrea O. Rossetti
Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010
Simon Faissner, Ralf Gold
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)
Tim L. Wigal, Jeffrey H. Newcorn, Nelson Handal, Sharon B. Wigal, Ioulietta Mulligan, Virginia Schmith, Eric Konofal
Author Correction to: l-Acetyl-carnitine in Patients with Carpal Tunnel Syndrome: Effects on Nerve Protection, Hand Function and Pain
Giorgio Cruccu, G. Di Stefano, F. Fattapposta, S. Jann, L. Padua, A. Schenone, A. Truini